Senhwa Biosciences, Inc. Employee Directory
Biotechnology ResearchTaipei City, Taiwan11-50 Employees
Senhwa Biosciences, Inc. is a biotechnology research company focused on developing first-in-class therapeutics for oncology, rare diseases, and immunotherapy. It is headquartered in Taipei, Taiwan, with an operational base in San Diego, California, and it employs 11 to 50 people. The company's lead programs are two first-in-class small molecules, CX-5461 and CX-4945, both in Phase I/II clinical trials across Australia, Canada, the United States, Korea, and Taiwan. CX-5461 acts as a G-quadruplex stabilizer that induces tumor DNA damage through synthetic lethality in BRCA1/2-mutant or HR-deficient contexts, while CX-4945 is a selective CK2 inhibitor that can inhibit phosphorylation of XRCC1 and enhance the activity of DNA-damaging chemotherapy. In November 2024, Dr. Yiu-Lian Fong was appointed corporate Director, and in March 2026 Bestat Pharmaservices Corp. integrated with Senhwabio to establish Taiwan's first complete one-stop CRO platform for new drug R&D services.